aTyr Pharma Announces Positive End-of-Phase 2 Meeting with FDA on Efzofitimod for the Treatment of Pulmonary Sarcoidosis

10.03.2022 - Regulatory path forward supports company’s intention to initiate a planned registrational study in the third quarter of 2022.SAN DIEGO, March 10, 2022 (GLOBE NEWSWIRE) - aTyr Pharma, Inc. (Nasdaq: LIFE) (aTyr or the “Company”), a biotherapeutics ... Seite 1

Related Keywords

Sanjays Shukla ,Robert Baughman ,Atyr Pharma Inc ,Drug Administration ,University Of Cincinnati Medical Center ,Nasdaq ,Tyr Pharma ,Typeb End Of Phase ,Chief Executive Officer ,Cincinnati Medical ,